Brief: Santhera Signs Agreements In Gene Therapy Research For Congenital Muscular Dystrophy
May 6 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
SANN.S :
* SANTHERA SIGNS AGREEMENTS IN GENE THERAPY RESEARCH FOR
CONGENITAL MUSCULAR DYSTROPHY WITH RUTGERS UNIVERSITY
* SANTHERA GAINS RIGHTS TO INTELLECTUAL PROPERTY DEVELOPED
AT
RUTGERS ON CERTAIN GENE CONSTRUCTS THAT WILL BE FURTHER STUDIED
UNDER A COLLABORATION AGREEMENT.
Source text for Eikon: ID:nGNE3750S1
Further company coverage: SANN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Santhera Pharmaceuticals Holding AG
See all newsSwitzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -6.562 Million
Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
Brief: Santhera Gets Positive CHMP Opinion To Expand Agamree (Vamorolone) Use
Brief: Santhera Pharmaceuticals H1 Operating Income CHF -35.444 Million